Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Metabolism & Endocrine
Filter     Order     Display # 
Date Item Title Hits
16 Mar 2010 Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation of Beta Cell Function 6
16 Mar 2010 A Once-Monthly Formulation of Risedronate Sodium Hydrate for the Treatment of Osteoporosis Entered Into Phase 3 Clinical Programs in Japan 5
15 Mar 2010 NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance 8
15 Mar 2010 Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission 6
15 Mar 2010 Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet 6
15 Mar 2010 Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy 5
15 Mar 2010 FDA Requests Additional Information Regarding AFREZZA(TM) in Complete Response Letter to MannKind 6
15 Mar 2010 Alnylam and Collaborators Present New Pre-Clinical Research on RNAi Therapeutics Targeting PCSK9 3
12 Mar 2010 ’Ipsen Grants Rhythm Exclusive Worldwide License 7
12 Mar 2010 XOMA 052 Phase 2 Trial Initiated in Type 1 Diabetes Patients 10
11 Mar 2010 Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies 5
09 Mar 2010 Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction 16
08 Mar 2010 Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx 14
03 Mar 2010 Novo Nordisk receives FDA approval for Norditropin FlexPro for growth hormone treatment (3 March 2010) 9
03 Mar 2010 Transition Therapeutics Announces Licensing and Collaboration Agreement With Lilly 157
01 Mar 2010 FDA Accepts VIAject(R) NDA for Review 32
26 Feb 2010 Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 12
24 Feb 2010 Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA) 54
23 Feb 2010 Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297 18
22 Feb 2010 Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity 12
17 Feb 2010 Marcadia Initiates Phase 1 Clinical Trial of GLP-1/GIP Dual Agonist MAR701 44
14 Feb 2010 Idera Pharmaceuticals Presents Preclinical Hyperlipidemia Data on a Toll-like Receptor Antagonist at Keystone Symposium 33
11 Feb 2010 Roche study drug may offer valuable new treatment option for patients with type 2 diabetes 18
11 Feb 2010 Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naļve Patients with Type 1 Gaucher Disease 15
11 Feb 2010 Two-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Continued Improvement Across All Endpoints 16
11 Feb 2010 Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium 17
11 Feb 2010 Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease 14
10 Feb 2010 Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint 12
09 Feb 2010 XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients 17
09 Feb 2010 Penwest Initiates Second Phase IIa Clinical Trial for A0001 21
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1524

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

Oncology Market Leaders
Order Now

Subscribe La Merie Biologics